Congenital heart disease (CHD) is the most common class of major malformations in humans. The historical association with large chromosomal abnormalities foreshadowed the role of submicroscopic rare copy number variations (CNVs) as important genetic causes of CHD. Recent studies have provided robust evidence for these structural variants as genome-wide contributors to all forms of CHD, including CHD that appears isolated without extra-cardiac features. Overall, a CNV-related molecular diagnosis can be made in up to one in eight patients with CHD. These include de novo and inherited variants at established (chromosome 22q11.2), emerging (chromosome 1q21.1), and novel loci across the genome. Variable expression of rare CNVs provides support for the notion of a genetic spectrum of CHD that crosses traditional anatomic classification boundaries. Clinical genetic testing using genome-wide technologies (e.g., chromosomal microarray analysis) is increasingly employed in prenatal, paediatric and adult settings. CNV discoveries in CHD have translated to changes to clinical management, prognostication and genetic counselling. The convergence of findings at individual gene and at pathway levels is shedding light on the mechanisms that govern human cardiac morphogenesis. These clinical and research advances are helping to inform whole-genome sequencing, the next logical step in delineating the genetic architecture of CHD.
Genome-wide rare copy number variation (CNV) is now recognised as an important contributor to congenital heart disease (CHD). This review surveys recent advances in the field of structural genomics, with the goal of informing both the clinical translation of findings and the anticipated future wave of whole-genome sequencing (WGS) studies. Herein, CHD refers to major malformations of the heart or great vessels present at birth. Cardiomyopathies, vasculopathies and cardiac arrhythmias are excluded. The focus is on findings from large-scale genome-wide studies of submicroscopic germline CNV, and not on chromosomal abnormalities detectable on karyotype, case reports or small case series of individual CNVs, or deletion/duplication analyses of individual genes.
Clinical description and epidemiology of CHD
CHD is the most common class of major congenital anomalies in humans, and a major source of morbidity and paediatric mortality around the world.1,
Beginning at 3 weeks of embryonic life, the heart is the first organ to start developing in the human embryo.14 An overview of the complex sequence of events that results in a well-formed heart at birth is beyond the scope of this review.14 Disruption of any developmental step can result in a cardiac malformation. Anatomical, functional and clinical categorisations exist for the myriad described cardiac lesions (Figure 1). Advances in imaging technology have led to improved diagnostic precision.7 Various constellations of multiple defects can be found together, and can result in more complex CHD, of which tetralogy of Fallot (TOF) is the most common form (Figure 1).11,12 CHD may occur in apparent isolation, or in conjunction with other, extra-cardiac features (syndromic CHD). Overall, individuals with CHD are at increased risk for extra-cardiac congenital anomalies and for neurodevelopmental problems.15,16
With advances in paediatric surgery, the prevalence of individuals living with CHD is increasing in many areas of the world.2,3 Adults with CHD now outnumber affected children.17 With increased longevity, there is more attention on long-term outcomes and causation. Evidence from family and twin studies supports a genetic aetiology for CHD.18,
Context: early studies of chromosomal imbalances in CHD
Major chromosomal anomalies including aneuploidies have been associated with CHD for over half a century.20 The major aneuploidies compatible with postnatal life are traditionally associated with certain types of CHD: Down syndrome/trisomy 21 (atrioventricular canal defect), Edward syndrome/trisomy 18 (ventricular septal defect or VSD, pulmonary stenosis), Patau syndrome/trisomy 13 (VSD, atrial septal defect, transposition of the great arteries or TGA), Turner syndrome/monosomy X (coarctation of the aorta, aortic stenosis, VSD), and Klinefelter syndrome/XXY (Ebstein anomaly, TOF).26 It is important to note however that a broad spectrum of CHD has been observed within each of these syndromes.
Although genome-wide, the resolution of karyotype is low, rarely identifying structural anomalies less than 5–10 Mb in size. Chromosomal abnormalities visible on karyotype often involve deletion or duplication of hundreds of genes, and expression of complex developmental phenotypes.20,27 Karyotype was thus not often helpful to identify individual genes important to cardiac morphogenesis. Over 20 years ago, a technological advance became clinically available that used targeted probe testing with fluorescence in situ hybridisation to provide a molecular diagnosis for selected microdeletion syndromes associated with CHD.20 Testing required a high clinical index of suspicion and knowledge of the targeted syndrome to allow the specific probe to be ordered.
Fluorescence in situ hybridisation was instrumental in revealing the presence of submicroscopic structural anomalies associated with identifiable genetic syndromes, e.g., 7p11.23 and 22q11.2 deletions, respectively, for Williams–Beuren syndrome and 22q11.2 deletion syndrome (22q11.2DS), the latter formerly known as DiGeorge/velocardiofacial syndrome.28,29 Studies of these recurrent, usually de novo, 1.5–3 Mb sized CNVs have proven useful to identify individual genes (ELN at the 7p11.23 locus and TBX1 and CRKL at the 22q11.2 locus) that are important in cardiac morphogenesis.28,29 Animal models with genetically engineered deletions and point mutations of selected genes have been instrumental in these studies.28,
These early findings have left the impression that most chromosomal anomalies associated with CHD: (i) arise as de novo mutations; (ii) usually result in multiple congenital extra-cardiac features making them readily identifiable in the newborn period; (iii) have a rather specific pattern of associated CHD per individual syndrome (e.g., supravalvular aortic stenosis in Williams–Beuren syndrome); and (iv) individually account for relatively few patients with CHD. It would take new molecular technologies to reveal otherwise.
Genome-wide CNV in health and disease
A breakthrough discovery in 2004 showed that structural genomic variants (CNVs) are, as a class, common in the general population.31,32 These include both losses (deletions) and gains (duplications) with diverse potential mechanisms of action (Figure 2).33 CNVs are not inherently pathological. Within any individual’s genome, there are typically both myriad common (i.e., >1–5% frequency in the general population), and one or more rare, CNVs. The mutation rate of structural rearrangements like CNVs is much higher than that of single base pair changes, and CNVs may disrupt none, one, or several genomic elements (Figure 2).31,
Genome-wide CNV in CHD
Over the past decade strong evidence has accumulated that genome-wide rare CNV represents a considerable source of the genetic variation that contributes to CHD susceptibility.37,
Increased overall burden of rare CNVs
A consistent finding across multiple genome-wide studies is that there is an excess burden of rare CNVs in CHD compared with control populations (Table 1).38,
Increased burden of de novo CNVs
Restricting to rare CNVs that have arisen as de novo mutations shows similar excess burden findings in CHD, even after excluding 22q11.2 deletions (Table 2). Few studies employed direct control populations; however, the general population rate of de novo CNVs is well studied in other cohorts and typically quoted as <2%.47,57 One study involving patients with TGA reported a lower de novo mutation rate than for other cardiac lesions.55 This would be consistent with offspring recurrence data for TGA that suggest fewer dominant-acting mutations for this CHD.53 However, the numbers of patients studied to date is too small to draw firm conclusions (Table 2). The elevated de novo CNV mutation rate in other severe CHD may in part explain how it is maintained in the population, despite a strong negative selective pressure and before the advent of modern paediatric surgery. Although rare de novo mutations are of interest and often considered to be more highly penetrant, it is important to note that most CNVs, even rare CNVs known to be pathogenic, are inherited. Moreover, recurrent CNVs that arise de novo in some patients are inherited from parents without CHD in others (see below), consistent with variable expression and in some cases reduced penetrance.
22q11.2 deletions and duplications
The role of 22q11.2 deletions in CHD was well delineated before the advent of chromosomal microarray analysis (CMA).29 Cumulative prevalence estimates of this recurrent 22q11.2 deletion include ~50% in interrupted aortic arch type B, ~33% in truncus arteriosus, ~15% in TOF and 5–10% in VSD.29,59 Appreciation for other genome-wide rare recurrent and non-recurrent CNVs in CHD more generally has served to reinforce the importance of 22q11.2 deletions as the archetypal model for continued genetic discovery and clinical translation of findings. From a molecular genetic perspective, human and animal studies are shedding light on the specific determinants of cardiac expression (Box 1). From a clinical perspective, diagnosis is helpful and changes management, including genetic counselling.29,61,62
General features of 22q11.2 deletions are proving to be generalisable to other CNVs associated with CHD. Although enriched for conotruncal and other anomalies, all types of CHD have been associated with 22q11.2 deletions. Severity ranges from non-viable (fetal and early pregnancy loss) to subclinical, e.g., spontaneously closing VSDs. Many patients do not have a CHD phenotype. If ascertainment is not through congenital cardiac clinics, the prevalence of readily detectable CHD may be as low as ~25–40%.63 Although multi-system expression is the norm over the lifetime, readily detectable congenital anomalies may not be present.29 The CHD may appear ‘isolated’, especially prenatally or at birth, as neurodevelopmental and neuropsychiatric features may not become apparent for years or decades.29,61,62 Dysmorphic features are usually subtle, and absence of ‘typical’ facial features does not affect the likelihood of the diagnosis being present or the severity of the presentation.29 Mortality is significantly increased,29 and surgical and perioperative complications in those with 22q11.2 deletions and conotruncal anomalies can be greater than other patients with the same CHD.64 The deletion may be inherited or de novo. If inherited, the parent with the deletion will often not have CHD or, if present, the same CHD or other features as the affected proband.29 There is a high mutation rate in the population due to the local genomic architecture: flanking segmental duplications and resulting increased risk of non-allelic homologous recombination during meiosis. The reciprocal duplication can result in similar phenotypes, including CHD.29,65
1q21.1 deletions and duplications
One of the first loci to be identified from genome-wide studies of CNV in CHD was the recurrent 1q21.1 CNV. Sometimes occurring as a deletion,66 but more commonly as a duplication, this is a highly replicated finding, especially in TOF where the prevalence appears to be just less than one in every 100 patients (Figure 3).38,39,45,47,50,55,57,67,68 As for all CNVs associated with CHD, the expression is variable, even within families, for both cardiac anomalies and other phenotypes, and is not necessarily correlated with the length of the CNV.38,40,47,52,67,69 1q21.1 duplications are rare in control populations, e.g., in five out of 18,828 controls (0.027%) from three studies, where some controls were not screened for disease (reviewed in ref 67). Although it is uncertain if any single gene at this locus can be designated as truly causal, the most evidence points to the GJA5 gene that encodes connexin 40,38,68 a cardiac gap junction protein expressed in the right ventricular outflow tract.45 Point mutations in GJA5 can be associated with atrial fibrillation.70
8p23.1 deletions overlapping GATA4
Before the first wave of genome-wide CNV studies, the 8p deletion syndrome and sequence mutations in GATA4 were both reported to be associated with CHD.14,71,72 Haploinsufficiency of GATA4 is now one of the most frequent rare structural anomalies identified in genome-wide CNV studies of CHD.34,39,41,47,48,50,52,58 Unlike the typical chromosomal rearrangements at 1q21.1, 15q11.2 and 22q11.2 mediated by non-allelic homologous recombination, these 8p deletions are non-recurrent and of varying size. Haploinsufficiency of adjacent genomic elements like SOX7 may shape the cardiac expression.41,73 Duplications at the 8p23.1 locus have also been reported in CHD.48,50,58,60 The spectrum of cardiac lesions favours septal defects, including atrioventricular canal defects,52 but as for other loci there is significant cardiac phenotypic heterogeneity. GATA4 encodes an essential cardiac transcription factor that works in concert with other key regulators of cardiac morphogenesis like NKX2-5 and TBX5.14,71
The putative association of 15q11.2 deletions with CHD illustrates the complexity imbued by incomplete penetrance, non-cardiac phenotypic expression, and ascertainment. Proximal deletions in this complex region (breakpoints BP1-BP2) on chromosome 15 are risk factors of modest effect for neurodevelopmental and neuropsychiatric disorders.34,74,
Two early studies reported that individuals with this 15q11.2 deletion were moderately enriched in cohorts with diverse CHD, relative to control populations.34,39 However, one study had an increased burden of extra-cardiac phenotypes in cases,34 and the other had a low prevalence in the controls used (one in 1,538).39 Since then, 15q11.2 deletions have been identified infrequently in genome-wide CNV studies of CHD.57 Case series of individuals with 15q11.2 deletions ascertained through clinical testing for developmental phenotypes or multiple congenital anomalies report variable rates of CHD,74,
Pathway analyses and gene families
Interpreting genome-wide CNVs is challenging, as individual variants are rare and often involve multiple genomic elements. Also, non-knockout mutation dosage changes in most genes are uncharacterized in both humans and model organisms. Several studies have applied pathway and gene enrichment analyses of varying degrees of sophistication to rare CNV datasets to identify gene sets important to cardiac development. Although most were limited in scope, there are significant results for not only functional gene sets that would be expected (vascular development/cardiac structure)47 but also for more novel gene sets: WNT signalling,39 ‘gene neighbours’ (with shared genetic or physical interactions) of GATA4/TBX5/NKX2-5,38,57 angiogenesis,40 semaphorin-plexin pathways,38 ciliary proteome,38,48 TGF-beta signalling48 and neuron projection.38 The latter is notable because of the high rate of neurodevelopmental problems in patients with CHD, and similar findings from a large whole-exome sequencing study.78 There is also overlap with arrhythmogenic genes initially implicated in electrical/functional as opposed to structural heart abnormalities (e.g., GJA5 and CACNA1C).38,53,68,77 CNV overlap of non-protein-coding genes like microRNAs is less well studied but may also implicate cardiac pathways.79,80
Clinical genetic testing with CMA
Diagnosis of microdeletion and microduplication syndromes previously necessitated a high index of suspicion for classic clinical features that may or may not be present. CMA (also known as array comparative genomic hybridisation) is a clinical genetic test that allows for the identification of not only the individually rare CNVs underlying these established syndromes but also other emerging ‘genomic disorders’ across the genome. Initial consensus testing indications for CMA were multiple congenital anomalies and/or developmental delay/intellectual disability/autism spectrum disorder.35 Various outcomes are possible with CMA (Box 2).
The clinical yield of CMA in CHD has been best described in the prenatal setting. Jansen et al.81 identified 13 publications that included 1,131 cases in their meta-analysis of array comparative genomic hybridisation studies in prenatally diagnosed CHD. The incremental yield (i.e., excluding aneuploidy and 22q11.2 deletions) of clinically relevant CNVs was 7.0%; 3.4% in ‘isolated’ CHD and 9.3% in syndromic CHD.81 When including 22q11.2 deletions, the overall yield was 12% (about one in eight).81 An additional benefit of CMA was in the detection of atypical 22q11.2 deletions that are not detectable using standard probes in targeted fluorescence in situ hybridisation testing. VUS were identified in an additional 3.4% of CHD fetuses.81 Thus for pre-test counselling, one might predict a 14% chance of uncovering an anomaly on CMA that is deemed clinically reportable: 4% 22q11.2 deletion, 7% other pathogenic CNV and 3% VUS.81 One caveat is that pathogenic CNV included both those variants implicated in CHD, as well as ‘incidental’ findings relevant to neurodevelopment. The largest component study82 drove most of the significant findings in this meta-analysis. As more knowledge accumulates, original results of such genetic testing need to be re-annotated with respect to pathogenicity. Postnatal studies support a similarly high and increasing yield of pathogenic CNVs in both isolated and syndromic CHD cohorts,83,84 as well as a high rate of VUS.85 As expected, the yield is consistently higher in individuals with syndromic CHD.51,83
Indications for genome-wide testing are likely to expand. In practice, CMA is now often offered for apparently isolated forms of serious CHD.84,85 Some have advocated for the universal postnatal use of CMA in isolated CHD.86 In consanguineous families, single-nucleotide polymorphism arrays offer the added benefit of determining regions of loss of heterozygosity, which may then direct targeted sequencing of recessive genes implicated in cardiovascular development. The cost of testing and the current high rate of VUS are important disadvantages. Another major caveat is that most single gene disorders are not detectable with CMA. Patients, families and clinicians may mistakenly conclude on the basis of a normal CMA result that an identifiable genetic contribution to the CHD has been ruled out (Box 2). The application of CMA, while helpful for providing a molecular diagnosis for a significant minority of patients with CHD, is not a replacement for a comprehensive medical genetic evaluation.
Recurrence risk estimation and genetic counselling
Genetic counselling in CHD has traditionally relied upon empiric recurrence risk values,87,88 but rare CNVs can have a significant impact in specific cases. As in other domains, classic microdeletion syndromes like 22q11.2DS are the archetypal example of clinical applicability. Other genetically diagnosable subtypes of CHD promise similar possibilities with respect to changing standard recurrence risk prediction and genetic counselling.67,87,88
Incorporating rare CNVs into risk prediction and counselling requires a nuanced approach. Careful phenotyping and genotyping of the parents is essential.87 A de novo CNV may be mistaken for the sole, causal variant in an individual with CHD. In one example, a subject with left-sided CHD and a de novo partial 1q21.1 duplication also inherited two rare CNVs overlapping candidate genes for CHD from a less severely affected father.40 De novo rare CNVs can seemingly have no, or subclinical deleterious effects. Parental germline mosaicism is also a consideration. In one recent study of rare CNV in CHD, the parents of two out of 20 affected probands with apparently de novo CNVs were ultimately found to have low level mosaicism in serum.47
Most rare CNVs are inherited. Some, such as 22q11.2 deletions, are recurrent and/or have been observed in unrelated individuals, while others are ultra-rare or unique to a particular family (private). Inheritance of a CNV from a purportedly unaffected parent can be falsely reassuring. As discussed above, variable expression of cardiac phenotypes is the norm. The effects of high but incompletely penetrant mutations on reproductive fitness in the parental generation are an important source of bias.89,90 A parent may also have a subclinical cardiac phenotype (e.g., bicuspid aortic valve demonstrates familial recurrence with hypoplastic left heart syndrome91) or a non-cardiac phenotype that may not be readily apparent. Alternatively, inheritance of any variant from an affected parent has an a priori likelihood of at least 50%. Co-segregation of a variant with CHD within a nuclear family (i.e., from affected parent to affected child) is thus suggestive but not specific. Two large-scale studies have considered multiplex nuclear families,40,47 but none to date have adjudicated CNVs within the extended family context. Counselling always needs to emphasise the potential for considerable variability in the type and severity of CHD, and in any extra-cardiac manifestations.
Prognostication in paediatric probands and concerns about sibling recurrence were previously the primary impetus for clinical genetic testing and counselling. With improved childhood survival, there is growing interest in issues germane to adults with CHD,10,
Clinical prognostication and prediction of extra-cardiac features
Rare CNVs are associated with a range of developmental disorders and major extra-cardiac phenotypes.33,34,92 Available data suggest that ‘syndromal’ patients with TOF, including those with recognisable genetic syndromes, have worse surgical outcomes and worse 10-year actuarial survival.93,94 Gaynor et al.95 showed that neurodevelopmental outcomes were also significantly worse in infants with CHD who had confirmed or suspected genetic syndromes. Notably, patient-specific factors were more important predictors of worse neurodevelopmental outcomes than intraoperative factors.95 There is a clinical impetus to better understand and predict phenotypic expression of rare CNVs across the lifespan, particularly as regards surgical and neurodevelopmental outcomes. In general, the larger and rarer the rearrangement the more easily observable the phenotypic effects.33 Given comparably sized rearrangements at the same locus, deletions usually have more severe phenotypic effects than duplications.33 Last, extra-cardiac features can appear later in life.61,77,92,96 For this reason, the ‘syndromic’ label is difficult to apply reliably and may be misleading, particularly in children and in the prenatal setting.
Two studies have explored the potential consequences of large rare CNVs on early outcomes, after excluding aneuploidies and 22q11.2 deletions. Carey and colleagues studied 223 patients with single-ventricle CHD and data on neurocognitive and growth outcomes at 14 months.58 They identified putatively pathogenic rare genic CNVs >300 kb in size in 14% (25 duplications and six deletions), including CNVs associated with genomic disorders in 13 patients. Comparing those with a deletion or duplication (CNV+) to those without such a CNV showed some subtle effects on growth associated with duplications, and worse neurocognitive outcomes on one of two measures in the small subgroup with deletions. Of note, worse neurodevelopmental outcomes are associated with large deletions in other populations without CHD.97,98 As anticipated, worse neurocognitive outcomes were associated with the genomic disorders associated with recurrent CNVs.58 Only three out of the 14 subjects examined in the CNV+ group had dysmorphic features or significant extra-cardiac phenotypes.58 Recently, Kim et al.54 reported that the presence of a rare genic CNV >300 kb in size was also independently associated with decreased transplant-free survival in a separate cohort of 422 children with non-syndromic CHD.
With increasing survival into adulthood, genetic factors that may inform longevity and reproduction are clinically, as well as scientifically, relevant. Late cardiac complications result in significant morbidity and mortality; however, not all patients develop adverse late outcomes (cardiac or extra-cardiac).10,
Insights into human cardiac development, and implications for discovery-based science
Several genetic mechanisms and many genes are involved in increasing susceptibility to CHD. Microarray technology for genome-wide CNV detection has greatly accelerated the pace of discovery of new candidate genes and pathways. Ongoing research to delineate copy number variable regions in the genome and measure their frequencies in the general population, at ever-higher resolutions, is key to being able to interpret results from disease populations. Efforts to catalogue CNV loci associated with CHD are valuable (see, e.g., the meta-analysis by Thorsson et al.52), but any such list requires regular updating and revision.
CNVs can narrow critical regions for CHD, including those previously implicated by large karyotypically-visible anomalies. Hundreds to thousands of protein-coding genes are expressed in the human heart or great vessels at some point in early development. The complex interplay of multiple proteins and regulatory elements may lead to relative weak spots susceptible to disruption by mutations, yet this susceptibility is balanced by the innate redundancy of these systems. Disruption of normal cardiac morphogenesis requires overcoming the robustness of genetic networks that have been fine-tuned through evolution. By virtue of their size and mutational frequency, CNVs can simultaneously disrupt multiple genes and/or regulatory elements within an individual (Figure 2), and this could be why CNV is so important to CHD causation. In addition to the examples provided above, studies involving the 1p36 deletion syndrome nicely illustrate this concept, as well as the associated challenges in ascribing causality to specific genes.101,
The considerable variability in the type and severity of CHD associated with individual recurrent CNVs provides further support for, and new insights into, the genetically and functionally interdependent pathways that govern cardiogenesis. There appears to be significant shared underlying genetic susceptibility to lesions considered anatomically discrete, akin to the genetically related spectrum of seemingly disparate neurodevelopmental disorders.34,92 Combining clinically distinct CHD (e.g., multiple conotruncal defects) can increase power for rare variant identification and analyses.39,53,57 Common and rare genetic modifiers of expression remain to be discovered (Box 1).
Individually rare CNVs—gains and losses, inherited and de novo—are collectively important genetic factors contributing to abnormal heart and great vessel development in humans. All rare variants sufficiently studied to date are characterised by some degree of variable cardiac and extra-cardiac expression. Many also display reduced penetrance. Estimating these parameters is challenging, and can be confounded by ascertainment bias and reproductive fitness effects.19,67,89,90 The individual rarity of non-recurrent CNVs has meant that there is often insufficient evidence (be it epidemiology, cell biology or model organism-based) to conclude causality. Large human sample sizes including the wealth of data generated from clinical use of CMA, high-throughput model organism screening,106 and targeted mutagenesis using CRISPR/Cas9 technology will all help in this endeavour.
Epistatic interactions are not well studied in human CHD. Our ability to provide increasingly personalised counselling will be determined by our understanding of modifiers of expression. Elegant experiments in mice with heterozygous Nkx2-5 mutations demonstrate the layers of complexity that we can expect to encounter even in individuals with pathogenic single-gene mutations.107,108 For CNV, genome-wide molecular studies in cohorts with 22q11.2 deletions provide the template for studying other recurrent variants (Box 1). For example, an immediate next step for many CNVs would be to carefully define the breakpoints and study the intact allele (Figure 2). The success of this approach is best illustrated by distal 1q21.1 deletions causing TAR syndrome.109
In our experience, the primary hope of many families and clinicians is that prenatal or early postnatal genetic, e.g., CMA, testing will help in predicting neurodevelopmental outcomes. This has not been the focus of most studies reviewed herein. However, research on CNV in CHD has been occurring in parallel with studies of developmental delay/intellectual disability, autism spectrum disorder and schizophrenia.33,
There is an impetus to consider in a similar fashion to CNV and structural variation the contribution of rare sequence-based changes to the genetic architecture of CHD. New genetic technologies have proved useful in advancing our understanding of CHD aetiopathogenesis, and increasing clinical diagnostic yield. Recently, whole-exome sequencing has begun to facilitate novel gene discovery.78,111 In the two largest whole-exome sequencing study to date, Zaidi et al. and Homsy et al. demonstrated enrichment of de novo point mutations in individuals with severe CHD and identified multiple new candidate genes.78,111 Interpretation of rare sequence variants will be informed by genes and pathways identified through rare CNV. WGS is the next logical step in this progression. The ability to comprehensively assess sequence and structural changes in coding and noncoding sequence genome-wide within an individual with CHD will undoubtedly identify new mechanisms that govern human cardiac morphogenesis. WGS offers the promise of improved resolution with respect to structural variation compared with CMA. The path forward involves the application of WGS on a large-scale. This will need to be married with careful phenotyping, family studies, and other hallmarks of excellence in genetic discovery study design. Personal WGS as a single universal genetic test in CHD that is cost-effective and of broadly applicable clinical utility is a highly anticipated but future consideration.112
ASB holds the Canada Research Chair in Schizophrenia Genetics and Genomic Disorders, and the Dalglish Chair in 22q11.2 Deletion Syndrome. This work was supported by the University of Toronto McLaughlin Centre and Canadian Institutes of Health Research (MOP 97800). The authors thank Gladys Wong and Sean Bekeschus for assistance with manuscript preparation.